Print

HVTN 106

A Phase 1 Randomized, Double-Blind, Placebo Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of 3 Different HIV-1 DNA Priming Regimens (Nat-B Env, CON-S Env, and Mosaic Env) With MVA-CMDR Boosts in Healthy, HIV-1-Uninfected Adults

Trial Details:

I Ongoing
NIAID, CHAVI, IPPOX,MHRP, HIV Vaccine Trials Network December 31, 2014
MVA-CMDR,DNA Mosaic Env,DNA CON-S env,DNA Nat-B env DNA Nat-B Env, CON-S Env, and Mosaic Env; MVA gag-pol CM 240, env CM235
DNA Nat-B env DNA
DNA Mosaic Env DNA
MVA-CMDR Viral Vector - Pox
USA 105
NCT02296541
https://clinicaltrials.gov/ct2/show/NCT02296541